IP Library Granted Patent US 9,675,579
Granted Patent B2
US 9,675,579 · App. 14/785,055 · Granted Jun 13, 2017

Tetrahydrocannabivarin for use in the treatment of nausea and vomiting

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,675,579
App. No.
14/785,055
Granted
Jun 13, 2017
Kind
B2
Abstract

The present invention relates to the use of tetrahydrocannabivarin (THCV) in the treatment of nausea and vomiting. Preferably the THCV is isolated and/or purified from cannabis plant extracts. Preferably the nausea and/or vomiting is caused by the effects of a medication such as a chemotherapeutic agent.

Claims (12)

1. A method for treating nausea and/or vomiting comprising administering to a subject in need thereof a therapeutically effective amount of a phytocannabinoid tetrahydrocannabivarin (THCV), wherein cannabidiol (CBD) and cannabidivarin (CBDV) are not administered to the subject.

2. The method of claim 1 , wherein the nausea and/or vomiting is caused by the effects of a medication.

3. The method of claim 2 , wherein the medication is a chemotherapeutic medicine.

4. The method of claim 1 , wherein the THCV is present in an effective human daily dose to reduce or relieve nausea and/or vomiting.

5. The method of claim 4 , wherein the effective human daily dose of THCV is between 1 mg and 2000 mg.

6. The method of claim 5 , wherein the effective human daily dose of THCV is between 10 mg and 1000 mg.

7. The method of claim 1 , wherein the THCV is packaged for use for an extended treatment period.

8. The method of claim 7 , wherein the extended treatment period is at least 7 days.

9. The method of claim 1 further comprising administering the THCV in combination with one or more other medicinal substances.

10. The method of claim 1 , wherein the THCV is in an isolated or substantially pure form.

11. The method of claim 1 , wherein the THCV is in the form of a botanical drug substance.

12. The method of claim 11 , wherein all or a substantial proportion of tetrahydrocannabinol (THC) has been removed.

Assignments (5)
CHANGE OF NAME Recorded May 13, 2025
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 071097/0142 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER: 9685579 PREVIOUSLY RECORDED ON REEL 046609 FRAME 0822. ASSIGNOR(S) HEREBY CONFIRMS THE ASSET PURCHASE BY WAY OF DEED. Recorded Jan 30, 2019
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 048187/0401 →
ASSET PURCHASE BY WAY OF DEED Recorded Jul 23, 2018
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 046609/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2016
From: ROCK, ERIN; PARKER, LINDA; DUNCAN, MARNIE; STOTT, COLIN
To: GW PHARMA LIMITED
Reel/Frame 039174/0438 →